GlassScriptPhysician profile
Joanna Hummel
NPI 1407509110
$1,505.39
in general payments reported to CMS, 2019-2025
21 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $268 · 2023: $392 · 2024: $426 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $289.27 | 2022-2024 | Wegovy, Saxenda, Ozempic |
| Janssen Scientific Affairs, LLC | $229.49 | 2025 | Pipeline, Erleada |
| Janssen Biotech, INC. | $145.91 | 2025 | Rybrevant, Carvykti |
| Kowa Pharmaceuticals America, INC. | $130.88 | 2022-2023 | Livalo, Seglentis |
| Pfizer INC. | $118.36 | 2024 | |
| Abbvie INC. | $98.02 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.56 | 2022-2023 | Trintellix |
| Exact Sciences Corporation | $68.86 | 2023 | Cologuard Collection Kit |
| Si-Bone, INC. | $53.29 | 2024 | |
| Medtronic, INC. | $47.52 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Depuy Synthes Sales INC. | $38.50 | 2024 | Monovisc, Orthovisc |
| Lilly USA, LLC | $36.80 | 2024 | Mounjaro |
| Pacira Pharmaceuticals Incorporated | $29.77 | 2023 | Iovera, Zilretta, Exparel |
| Ibsa Pharma INC. | $29.49 | 2022-2023 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $22.94 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $20.10 | 2025 | Intrarosa |
| Astrazeneca Pharmaceuticals LP | $15.01 | 2024 | Airsupra |
| Currax Pharmaceuticals LLC | $14.86 | 2023 | Contrave |
| Mayne Pharma Commercial LLC | $14.33 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.81 | 2023 | Austedo |
| Amgen INC. | $13.62 | 2024 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Hummel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.